Cyclic Peptide: Physiology and What Research Reports

What a cyclic peptide is

A peptide is a short chain of amino acids linked by amide bonds. In a cyclic peptide, that chain is closed into a ring instead of ending in a free amino terminus and a free carboxyl terminus. The closure can be made in several ways: head-to-tail between the two termini, side chain to side chain, side chain to backbone, or through a disulfide bridge between two cysteine residues. A 2008 medicinal chemistry paper explored cysteine-constrained peptides as a way to present a constrained loop for targeting RNA (PMID 18065222).

The practical consequence is geometric. A linear peptide can rotate freely around many bonds and samples a large number of shapes in solution. Closing the ring removes rotational freedom, so the molecule spends more time in a smaller set of conformations. That pre-organisation is the central idea behind most of the chemistry described below.

Linear versus cyclic: a simple comparison

Where cyclic peptides come from

Cyclic peptides occur in nature and are also made synthetically. Many are microbial or fungal secondary metabolites. A 2022 natural products study isolated adiponectin-secretion-promoting cyclic peptide–polyketide hybrids from Colletotrichum gloeosporioides JS0417, a fungus associated with a halophyte plant (PMID 35172097). Adiponectin is a hormone released by adipose tissue, and the researchers used its secretion as the readout for that isolation work.

In the human body, the classical peptide hormones that readers usually encounter — insulin, oxytocin, vasopressin, somatostatin — are ribosomally made and processed in endocrine tissue, and several of them carry disulfide bridges that create a cyclic segment. So "cyclic peptide" is not a separate organ system or a single substance produced at one site; it is a structural category that cuts across natural products chemistry, endocrinology and synthetic drug design. A 2024 review in Angewandte Chemie discussed cyclic peptides as a class positioned between small molecules and biologics for drug development (PMID 37870189).

Why cyclisation matters to researchers

Two recurring themes appear in the published work. The first is stability: a closed ring has no free termini for exopeptidases to attack, and the constrained backbone is a common explanation offered for resistance to degradation. The second is membrane permeability, which is a long-standing obstacle for peptides of this size. A 2025 computational paper described an AI-driven approach to the de novo design of customisable, membrane-permeable cyclic peptides (PMID 40782270).

Design detail matters at the level of individual bonds. A 2023 study used molecular dynamics simulations to design and optimise cyclic peptide linkers, treating the linker as a tunable variable rather than an afterthought (PMID 37903231). A 2026 letter reported AI-guided design of cyclic peptide binders targeting TREM2 using a method the authors called CycleRFdiffusion, together with experimental validation of the designs (PMID 41435973).

How cyclic peptides are studied and measured

Because the category is structural, the methods vary with the question being asked.

• Synthesis and characterisation. Solid-phase synthesis followed by cyclisation, then purification and mass spectrometric and NMR characterisation.
• Computational modelling. Molecular dynamics was used to compare linker options before synthesis in one 2023 report (PMID 37903231), and generative models were used to propose new sequences in later work (PMID 40782270).
• Target binding assays. A 2021 paper described the discovery and development of cyclic peptide inhibitors of CIB1, an intracellular calcium- and integrin-binding protein (PMID 34795874).
• Enzyme substrate chemistry. A 2019 study in Molecules described cyclic peptide-based sirtuin substrates, using the constrained ring as a tool for probing deacylase enzymes (PMID 30682801).
• Microbiology. A 2022 paper reported antibacterial and antibiofilm activities of novel cyclic peptides tested against methicillin-resistant Staphylococcus aureus (PMID 35887376), and a separate 2022 study examined amphiphilic cyclic peptide [W₄KR₅] in combination with antibiotics as broad-spectrum antimicrobial agents (PMID 35339840).
• Materials and biomaterials. A 2019 Faraday Discussions paper described UV-responsive cyclic peptide progelator bioinks, in which the ring opens on irradiation to trigger gelation (PMID 31549115), and a 2020 Biomacromolecules study described a cyclic peptide mimetic of damaged collagen (PMID 32159956).

What the literature reports

Adverse Events: What Studies Report

The publications summarised on this page are chemistry, computational design, natural product isolation and preclinical assay reports. None of them were described as human safety or tolerability trials, and none of them reported clinical adverse events, dosing schedules or patient outcomes. The 2024 review discussed cyclic peptides as a class under development rather than reporting safety outcomes for any individual compound (PMID 37870189). The 2022 MRSA study was framed as an antibacterial and antibiofilm activity investigation of novel cyclic peptides rather than a safety study (PMID 35887376), and the 2022 combination paper examined amphiphilic cyclic peptide [W₄KR₅] with antibiotics as antimicrobial agents in laboratory testing (PMID 35339840). Because "cyclic peptide" is a structural category and not a single substance, safety cannot be generalised across it: each molecule carries its own profile, and none of the work cited here established one in humans. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or decision.

Limitations of the current evidence

Readers meeting the term should note three constraints. First, most of the cited work is in vitro, in silico or synthetic-chemistry work, so the study designs do not support conclusions about effects in people. Second, results reported for one ring — a CIB1 inhibitor, for instance (PMID 34795874) — say nothing about an unrelated cyclic peptide with a different sequence or target. Third, computationally designed molecules require laboratory confirmation; one 2026 report paired AI-generated TREM2 binder designs with experimental validation for exactly that reason (PMID 41435973).

References

• Cyclic Peptides for Drug Development (Angewandte Chemie International ed. in English, 2024)
• UV-responsive cyclic peptide progelator bioinks (Faraday Discussions, 2019)
• Cyclic Peptide Mimetic of Damaged Collagen (Biomacromolecules, 2020)
• Discovery and Development of Cyclic Peptide Inhibitors of CIB1 (ACS Medicinal Chemistry Letters, 2021)
• Cyclic Peptide Linker Design and Optimization by Molecular Dynamics Simulations (Journal of Chemical Information and Modeling, 2023)
• AI-driven de novo design of customizable membrane permeable cyclic peptides (Journal of Computer-Aided Molecular Design, 2025)
• Adiponectin-Secretion-Promoting Cyclic Peptide-Polyketide Hybrids from a Halophyte-Associated Fungus, Colletotrichum gloeosporioides JS0417 (Journal of Natural Products, 2022)
• Amphiphilic cyclic peptide [W(4)KR(5)]-Antibiotics combinations as broad-spectrum antimicrobial agents (European Journal of Medicinal Chemistry, 2022)
• Targeting RNA with cysteine-constrained peptides (Bioorganic & Medicinal Chemistry Letters, 2008)
• Antibacterial and Antibiofilm Activities of Novel Cyclic Peptides against Methicillin-Resistant Staphylococcus aureus (International Journal of Molecular Sciences, 2022)
• Cyclic Peptide-Based Sirtuin Substrates (Molecules, 2019)
• AI-guided design of cyclic peptide binders targeting TREM2 using CycleRFdiffusion and experimental validation (Bioorganic & Medicinal Chemistry Letters, 2026)